| Document |
Document Title |
|
WO/2018/042291A1 |
The present invention relates generally to compositions and methods of use that include compounds and compositions that treat and/or prevent virus infections such as mosquito borne flaviviruses Zika and dengue and alphavirus chikungunya ...
|
|
WO/2018/042437A1 |
Color conversion films for a LCD (liquid crystal display) having RGB (red, green, blue) color filters, as well as such displays, formulations, precursors and methods are provided, which improve display performances with respect to color ...
|
|
WO/2018/045217A1 |
Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effectiv...
|
|
WO/2018/042409A1 |
This invention is directed to photoluminescent compounds based on rhodamine dyes with green emission and uses thereof for photoluminescence based devices.
|
|
WO/2018/039376A1 |
The present invention relates to monoterpenoid and phenylpropanoid containing derivative compounds, methods of making the compounds, compositions comprising the compounds, and methods of repelling pests using the compounds and/or composi...
|
|
WO/2018/039282A1 |
This invention is directed to methods for the facile and accurate identification of cancer cells in a tissue sample, such as a surgical field. In particular, the compositions and methods employ conjugates comprising pro-fluorescent fluor...
|
|
WO/2018/037279A1 |
The present invention is directed to a class of anti-inflammatory, antioxidant nitroalkene compounds used in biological or biochemical applications to reduce oxidative stress or damage. The nitroalkene compounds described herein further ...
|
|
WO/2018/033088A1 |
Provided are a five-membered ring substituted compound having xanthone as the core and applications thereof. The compound has xanthone as the parent core and is connected to an aromatic heterocyclic group, thereby breaking molecular symm...
|
|
WO/2018/035296A1 |
Kinases can be engineered to utilize an ATP analog that is not readily utilized by wild-type kinases by introducing a mutation in the ATP-binding pocket. However, application of this method has been limited by the membrane impermeability...
|
|
WO/2018/031853A1 |
Disclosed is an optical compensation film made of a solution cast of a polymer blend comprising a nitrated styrenic fluoropolymer and a polyimide. The compensation film is a positive-C plate having reversed wavelength dispersion that is ...
|
|
WO/2018/030550A1 |
The present invention relates to a compound that may have an ROR(gamma)t modulating activity and can thus be useful in the treatment of cancer.
|
|
WO/2018/030786A1 |
The present specification provides a compound of chemical formula 1 and an organic light-emitting device comprising the same.
|
|
WO/2018/026538A1 |
Disclosed are folic acid or pteroic aicd conjugates and methods for using such conjugates. The conjugates described herein comprise a chemotherapeutic drug or imaging agent covalently bound thereto through a bond or via a linker that is ...
|
|
WO/2018/020974A1 |
Provided are the following: a sulfonium salt which does not contain a toxic metal and which exhibits higher cationic polymerization performance and crosslinking performance than a tetrakis(pentafluorophenyl)borate salt; a heat- or photo-...
|
|
WO/2018/022868A1 |
The present invention provides a plant-based flavonoid pharmaceutical composition and its synthetic for inhibition of phosphau'dylinositol-4-kinases and consequent prevention and treatment of RNA viruses including but not limited to vira...
|
|
WO/2018/023072A2 |
Disclosed are compounds of formula (I), and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
|
|
WO/2018/022899A1 |
O-substituted hydroxamic acids with carbon-based leaving groups as HNO donors are disclosed. Pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions also are disc...
|
|
WO/2018/018152A1 |
An orally administrable chewing gum formulation is provided comprising a pharmaceutically acceptable gum base and particles of a pharmaceutical agent ranging in size from about 50 to about 2000 µm, wherein the formulation comprises abou...
|
|
WO/2018/016634A1 |
Provided is a compound represented by formula (0). (0) (In formula (0): RY is a hydrogen atom, a C1–30 alkyl group, or a C6–30 aryl group; RZ is a C1–60 N-valent group or a single bond; each RT is independently an optionally-substi...
|
|
WO/2018/015593A1 |
The present invention relates to a combination comprising cromoglicic acid or derivatives thereof and to dermatological compositions comprising said composition. The invention also relates to the use of said combination or composition fo...
|
|
WO/2018/014388A1 |
A light-emitting material, a preparation method therefor, and an organic light-emitting diode made of the light-emitting material. The light-emitting material has a single structure, a determined molecular weight, good solubility and fil...
|
|
WO/2018/016648A1 |
Provided is a compound represented by formula (0).
|
|
WO/2018/014387A1 |
A light-emitting material of the structural general formula (I), a preparation method therefor and an organic light-emitting diode using said light-emitting material, Ar1 and Ar2 being selected from aromatic amino groups as represented b...
|
|
WO/2018/014403A1 |
Provided are a light-emitting material and method for fabrication thereof, and an organic light-emitting diode using said light-emitting material. The light-emitting material has a simple structure and determined molecular weight, and ha...
|
|
WO/2018/016615A1 |
Provided is a compound represented by formula (0). (0) (RY is a C1–30 alkyl group or a C6–30 aryl group; RZ is a C1–60 N-valent group or a single bond; and RT is a C1–30 alkyl group, a C6–30 aryl group, a C2–30 alkenyl group,...
|
|
WO/2018/016611A1 |
Provided is a novel therapeutic agent for glaucoma, which has an sGC-activating activity. A therapeutic agent for glaucoma or an ocular hypotensive agent, which contains, as an active ingredient, a compound represented by formula (I-a) o...
|
|
WO/2018/016614A1 |
This compound is represented by formula (0).
|
|
WO/2018/016640A1 |
Provided is a compound represented by formula (0). (0) (RY is a hydrogen atom, a C1–30 alkyl group, or a C6–30 aryl group; RZ is a C1–60 N-valent group or a single bond; and RT is an optionally-substituted C1–30 alkyl group, an o...
|
|
WO/2018/014406A1 |
A light-emitting material, a preparation method therefor, and an organic light-emitting diode using the light-emitting material. The light-emitting material has a single structure, a determined molecular weight, great solubility and film...
|
|
WO/2018/014028A1 |
Disclosed herein are novel compounds. Such compounds may be synthesized using a hexadehydro-Diels- Alder (HDD A) reaction. Also disclosed are organic devices including one or more disclosed compounds. The organic devices can include orga...
|
|
WO/2018/009861A1 |
The present invention provides fluorescent polyfluorene polymers or macromers with unique optical properties that are stable. The polymeric fluorophores are useful in various bioassays formats. The inventive polymers are useful in assays...
|
|
WO/2018/000093A1 |
A composition for facilitating eyelash and/or eyebrow growth which includes at least forskolin derived exclusively from coleus forskohlii and at least one keratmocyte growth stimulator. In some embodiments, the keratinocyte growth stimul...
|
|
WO/2017/221002A1 |
The present invention relates to a novel class of chromene-2-carboxamide compounds inhibitors of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and their use as anti-infe...
|
|
WO/2017/221269A1 |
The present invention pertains to the enhanced activity of (+) epicatechin over (-) epicatechin. The present invention is related to novel analogs of (+) epicatechin of the formula (I), which enhances the pharmacokinetics and therefore t...
|
|
WO/2017/216699A1 |
Subject-matter of the present invention are novel 3-ketocoumarins, a process for their preparation and their use as photoinitiators in photopolymerization reactions, advantageously in photopolymerization reactions for inkjet printing ink...
|
|
WO/2017/216362A1 |
Described are methods for producing cannabinoid prodrugs using enzyme-catalysed synthesis / chemical modifications as well as methods for formulating such prodrugs in a pharmaceutically acceptable form and their use as therapeutic agents...
|
|
WO/2017/215680A2 |
Disclosed are a chlorprothixene pharmaceutical composition and effects thereof for protecting cerebral ischemia reperfusion injuries. The chlorprothixene pharmaceutical composition provided in the present invention comprises chlorprothix...
|
|
WO/2017/215538A1 |
Provided are a Mannich base derivative of acetylchrysin having a structrue of general formula I and a use thereof, wherein R1 and R2 are each independently selected from an acetyl and organic secondary amine methylene, and only one of R1...
|
|
WO/2017/216426A1 |
The invention relates to process for converting berry and/or fruit materials to fractions comprising bioactive compounds, said process comprising the steps, where at least one berry material or fruit material selected from berries, fruit...
|
|
WO/2017/212059A1 |
The present invention relates to a new process of manufacturing of caged cyclofen-OH and derivatives thereof, of formula (I) or salts thereof, wherein n, R1, R1 ', R2, and R3 are as defined in the claims.
|
|
WO/2017/214529A1 |
This disclosure relates to techniques and methods to isolate and purify cannabinoids, such as CBDV, CBD, CBC, THCV, THC, CBN, CBG, CBDA, THCA, or CBGA. Evaporation and sonicating techniques are used to isolate and purify cannabinoids, su...
|
|
WO/2017/207539A1 |
The invention relates to tetrahydropyranyl lower alkyl esters and particularly tetrahydropyranyl acetates, a method for producing same using ketene, and the use of same as fragrant and aromatic substances.
|
|
WO/2017/202798A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6, X, Y, A1 and A2 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2017/205350A1 |
Molecular probes for detecting and imaging pancreatic cancer are disclosed. The probes are modified benzoxanthene fluorophores, which are selectively taken up by pancreatic cancer cells, such as pancreatic ductal adenocarcinoma cells. Em...
|
|
WO/2017/201581A1 |
The present invention relates to new desferrioxamine B-based compounds that may be useful to treat neurodegenerative diseases, to their preparation, and to compositions including the compounds. The present invention also relates to the u...
|
|
WO/2017/201531A1 |
Provided are a photoactive fluorophore, a photoactive ligand, and a photoactive complex. The photoactive fluorophore includes a photoactivatable derivative of an azetidine-containing Janelia-Fluor dye. The photoactive ligand includes a p...
|
|
WO/2017/195835A1 |
One purpose of the invention is to provide a technique for modifying polyphenols to suppress the occurrence of precipitation and turbidity in water without separate addition of food additives or conducting enzyme treatment. Modified poly...
|
|
WO/2017/194173A1 |
The present invention relates to methods for purifying one or two cannabinoid compounds using simulated moving bed chromatography, wherein the cannabinoid compound(s) is/are obtained in the extract and/or the raffinate with the total amo...
|
|
WO/2017/187321A1 |
The present invention provides for compounds of formula (I), wherein R1, m, Z, G1, R2, and R3 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment ...
|
|
WO/2017/185179A1 |
A method of increasing the self-renewal and/or expansion of hematopoietic stem and/or progenitor cells (HSPCs) is described. Inhibiting the activity and/or expression of cytochrome P450 1B1 (CYP1B1) and/or increasing the expression or ac...
|
